EMEA-002824-PIP01-20 - paediatric investigation plan

Telitacicept

Key facts

• Active Substance:
  Telitacicept
• Therapeutic area:
  Immunology-Rheumatology-Transplantation
• Decision number:
  P/0097/2021
• PIP number:
  EMEA-002824-PIP01-20
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of Systemic Lupus Erythematosus (SLE)
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  RemeGen, Ltd.

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  19/03/2021

Decision

P/0097/2021 : EMA decision of 19 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for telitacicept (EMEA-002824-PIP01-20)

Reference Number: EMA/73059/2021